Skip to content

Protara Therapeutics, Inc.

TARA

CIK 0001359931

← back to feed
Revenue (TTM)
$2.95M
0.0% YoY Q1 May 2026
Net Income (TTM)
−$57.91M
−28.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.26
+38.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-2,208.2%
Q1 May 2026
Net Margin
-1,964.5%
Q1 May 2026
Free Cash Flow (TTM)
−$59.67M
Q1 May 2026
Cash
$14.74M
Q1 May 2026
Total Debt
$370.79K
Q1 May 2026
Shares Outstanding
56.2M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings